While Sarepta has now consented to the FDA’s request to stop selling Elevidys, the company’s brief standoff with the agency ...

As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm ...

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

The patient, who was in a trial for a limb girdle gene therapy, is the third person to die this year after receiving a Sarepta gene therapy.

NEW YORK, July 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 ...

The Dow, S&P 500, and Nasdaq rose Thursday as the stock market digested data on retail sales and jobless claims.

At the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy, will carry a black box warning for acute liver injury and acute liver ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its outlook. Click for my SRPT stock update.

Shares of Sarepta Therapeutics SRPT surged more than 30% in after-market trading yesterday after the company announced a strategic restructuring plan focused on pipeline reprioritization and ...

Sarepta's stock is jumping Thursday morning after the company announced a restructuring plan. Thomas Fuller / SOPA Images / LightRocket via Getty Images ...

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sarepta Therapeutics's market position. Stay informed and make well-judged ...

Sarepta Therapeutics SRPT -2.17% is restructuring, laying off 36% of its workforce and making changes to its executive team. The restructuring is expected to save $400 million a year, the gene ...